Genrix Bio signed a commercialization cooperation agreement for Weikang Duta monoclonal antibody injection and Sileweimi monoclonal antibody injection
I'm LongbridgeAI, I can summarize articles.Genrix Bio has signed an exclusive cooperation agreement with CMS and RXILIENT for the exclusive rights to market Weikang Duta monoclonal injection and Sileweimi monoclonal injection. According to the agreement, Genrix Bio will receive an upfront payment and milestone payments, expected to total approximately RMB 510 million, while obtaining sales revenue in mainland China, the Asia-Pacific region, and North Africa. Tibet CMS and RXILIENT will respectively obtain exclusive commercialization rights for the aforementioned products in mainland China and other regions
According to the Zhitong Finance APP, Genrix Bio (688443.SH) announced that recently, the company signed exclusive cooperation agreements with the subsidiary of CMS Holdings Limited (referred to as "CMS") - Tibet CMS Pharmaceutical Development Co., Ltd. (referred to as "Tibet CMS") and RXILIENT MEDICAL PTE. LTD. (referred to as "RXILIENT") for the monoclonal antibody injection Weikangduta (GR2001 injection) and the monoclonal antibody injection Sileweimi (GR1801 injection). According to the agreements, the company will receive upfront payments, milestone payments, and services for commercialization promotion, while Tibet CMS will obtain exclusive commercialization rights for the two products in mainland China, and RXILIENT will receive exclusive licensing rights for the two products in the Asia-Pacific region, the Middle East, and North Africa, excluding mainland China.
According to the "Exclusive Cooperation Agreement for GR2001 Injection," Tibet CMS will obtain exclusive commercialization rights for Weikangduta monoclonal antibody injection in mainland China, RXILIENT will receive exclusive licensing rights for Weikangduta monoclonal antibody injection in the Asia-Pacific region, the Middle East, and North Africa, excluding mainland China. Genrix Bio will receive upfront payments and milestone payments of up to approximately RMB 260 million, sales revenue from mainland China, and supply revenue based on net sales adjustments from the Asia-Pacific region, the Middle East, and North Africa, excluding mainland China. At the same time, the company will pay Tibet CMS a promotion service fee based on the sales revenue in mainland China as stipulated in the agreement.
According to the "Exclusive Cooperation Agreement for GR1801 Injection," Tibet CMS will obtain exclusive commercialization rights for Sileweimi monoclonal antibody injection in mainland China, RXILIENT will receive exclusive licensing rights for Sileweimi monoclonal antibody injection in the Asia-Pacific region, the Middle East, and North Africa, excluding mainland China. Genrix Bio will receive upfront payments and milestone payments of up to approximately RMB 250 million, sales revenue from mainland China, and supply revenue based on net sales adjustments from the Asia-Pacific region, the Middle East, and North Africa, excluding mainland China. At the same time, the company will pay Tibet CMS a promotion service fee based on the sales revenue in mainland China as stipulated in the agreement